While the IHC assessment of PDL1 expression in tumor samples has emerged as a possible biomarker of susceptibility to immune checkpoint inhibitors, its potential use poses many questions and challenges for both oncologists and pathologists. This evidence concerns the gene CD274 and neoplasm.